Robert H Wiltrout

Robert H Wiltrout

UNVERIFIED PROFILE

Are you Robert H Wiltrout?   Register this Author

Register author
Robert H Wiltrout

Robert H Wiltrout

Publications by authors named "Robert H Wiltrout"

Are you Robert H Wiltrout?   Register this Author

50Publications

-Reads

Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

J Hepatol 2015 Nov 2;63(5):1181-9. Epub 2015 Jul 2.

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States. Electronic address:

View Article
November 2015

Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity.

Immunity 2015 Aug 28;43(2):240-50. Epub 2015 Jul 28.

Department of Dermatology, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA; Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA. Electronic address:

View Article
August 2015

Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.

PLoS One 2014 13;9(8):e102709. Epub 2014 Aug 13.

Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California, United States of America; Department of Internal Medicine, School of Medicine, University of California, Davis, Sacramento, California, United States of America.

View Article
April 2015

Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.

Eur J Immunol 2015 Apr 23;45(4):1148-58. Epub 2015 Feb 23.

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

View Article
April 2015

Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice.

J Exp Med 2014 Nov 3;211(12):2373-83. Epub 2014 Nov 3.

Department of Dermatology, Department of Pathology and Laboratory Medicine, Department of Radiation Oncology, and Department of Dermatology and Internal Medicine, University of California, Davis, Sacramento, CA 95817

View Article
November 2014

Natural killer activity: early days, advances, and seminal observations.

Crit Rev Oncog 2014 ;19(1-2):1-13

Offlce of the Director, National Cancer Institute, National Institutes of Health.

View Article
September 2014

CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Hum Immunol 2014 Jul 4;75(7):614-20. Epub 2014 May 4.

Cancer and Inflammation Program, NCI, Center for Cancer Research, Frederick, MD, United States.

View Article
July 2014

NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Int J Cancer 2013 Jan 13;132(1):9-18. Epub 2012 Jun 13.

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

View Article
January 2013

Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.

Hepatology 2012 Oct 11;56(4):1567-74. Epub 2012 Sep 11.

Cancer and Inflammation Program, NCI, Frederick, MD 21702, USA.

View Article
October 2012

Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.

PLoS One 2012 13;7(3):e33303. Epub 2012 Mar 13.

Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, United States of America.

View Article
August 2012

A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.

Oncoimmunology 2012 Jan;1(1):115-117

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick MD, USA 21702.

View Article
January 2012

Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation.

Biol Blood Marrow Transplant 2011 Dec 8;17(12):1754-64. Epub 2011 Sep 8.

University of Nevada, Reno, Department of Microbiology and Immunology, Reno, Nevada, USA.

View Article
December 2011

The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Immunotherapy 2011 Oct;3(10):1167-84

Laboratory of Experimental Immunology, Cancer & Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institute of Health, Frederick, MD 21702, USA.

View Article
October 2011

Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.

Int Immunopharmacol 2011 Jul 15;11(7):879-89. Epub 2011 Jan 15.

NCI Frederick, Building 560, Room 31-18 Frederick, MD 21702, USA.

View Article
July 2011

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Cancer Res 2011 Jun 3;71(12):4074-84. Epub 2011 May 3.

Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, NCI-Frederick, Frederick, Maryland 21702-1201, USA.

View Article
June 2011

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.

J Immunol 2011 Jan 10;186(2):838-47. Epub 2010 Dec 10.

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.

View Article
January 2011

Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.

Eur J Immunol 2010 Apr;40(4):1099-106

Basic Science Program, Laboratory of Molecular Immunoregulation, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD 21702-1201, USA.

View Article
April 2010

Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

J Autoimmun 2009 Nov-Dec;33(3-4):275-81. Epub 2009 Aug 13.

Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles Street, Frederick, MD 21702, USA.

View Article
January 2010

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Proc Natl Acad Sci U S A 2009 Nov 5;106(46):19455-60. Epub 2009 Nov 5.

Laboratory of Experimental Immunology, Cancer and Inflammation Program, NCI Frederick, Frederick, MD 21702, USA.

View Article
November 2009

Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

Cancer Res 2009 Aug 4;69(16):6615-23. Epub 2009 Aug 4.

Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute-Frederick, Maryland 21702, USA.

View Article
August 2009

Immunotherapy of cancer by IL-12-based cytokine combinations.

Expert Opin Biol Ther 2007 Nov;7(11):1705-21

National Cancer Institute, Cancer and Inflammation Program, Laboratory of Experimental Immunology, Center for Cancer Research, Frederick, MD 21702, USA.

View Article
November 2007

Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.

Cancer Res 2006 Nov;66(22):11005-12

Laboratory of Experimental Immunology, Science Applications International Corporation-Frederick, National Cancer Institute Center for Cancer Research, Frederick, Maryland, USA.

View Article
November 2006

Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.

Cancer Res 2004 Oct;64(19):6849-53

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA.

View Article
October 2004

Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.

Biol Blood Marrow Transplant 2004 Aug;10(8):534-9

Department of Microbiology and Immunology, University of Nevada, Reno, Nevada 89557, USA.

View Article
August 2004

Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

Cancer Cell 2004 Feb;5(2):111-2

Laboratory of Experimental Immunology, National Cancer Institute, Center for Cancer Research, Frederick, MD 21702, USA.

View Article
February 2004

Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.

J Immunol 2004 Jan;172(2):943-53

Laboratory of Experimental Immunology, National Cancer Institute-Center for Cancer Research, Building 560, Room 31-93, Frederick, MD 21702, USA.

View Article
January 2004

Activation of cutaneous protein kinase C alpha induces keratinocyte apoptosis and intraepidermal inflammation by independent signaling pathways.

J Immunol 2003 Sep;171(5):2703-13

Laboratories of Cellular Carcinogenesis and Tumor Promotion, Center for Cancer Research, National Cancer Institute/NIH, 37 Convent Drive, Bethesda, MD 20892, USA.

View Article
September 2003

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.

Cancer Res 2003 Jan;63(1):207-13

Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702-1201, USA.

View Article
January 2003

Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters.

Cancer Lett 2002 Oct;184(1):37-47

Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

View Article
October 2002

IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside.

Expert Opin Biol Ther 2002 Jun;2(5):513-24

Investigational Biologics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article
June 2002